tirzepatide blood clots Carrying excess weight is a known risk factor for clots, but could GLP-1 medications like Ozempic, Wegovy, and Mounjaro help lower that risk? New research suggests they might. Join us for Understanding Blood Thinners | Pradaxa®

Transparency: No hidden fees or extra charges

Ozempic has a half-life of approximately 165 hours (roughly seven days), allowing it to remain therapeutically active throughout the entire weekly dosing interval

Importantly, localized increases in GLP-1, such as that occur in the gut and portal vein, often have a more profound effect than systemic elevations, emphasizing the therapeutic potential of targeting regional activity rather than relying solely on systemic concentrations

Adverse events leading to trial discontinuation were 2.6% for the semaglutide group and 3.3% for the placebo group

[1] Testing Grounds: The Trials and Outcomes of AOD-9604 AOD-9604's lipolytic potential has made it a compelling molecule for scientists and medical professionals looking to harness its potential for therapeutic purposes